Jonas Schiffmann1,2, Alexander Haese3, Katharina Boehm4, Georg Salomon3, Thomas Steuber3, Hans Heinzer3, Hartwig Huland3, Markus Graefen3, Pierre I Karakiewicz5,6. 1. Martini Clinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany - schiffmann.jonas@gmx.de. 2. Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada - schiffmann.jonas@gmx.de. 3. Martini Clinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany. 4. Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 5. Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada. 6. Department of Urology, University of Montreal Health Center, Montreal, Canada.
Abstract
BACKGROUND: Patients treated with robot-assisted radical prostatectomy (RARP) are frequently selected according to more favorable characteristics. Such patient selection might decrease according to increasing experience. METHODS: We relied on the Martini Clinic Prostate Cancer Center database and focused on patients treated with RARP between 2004 and 2013. Differences in clinical, pathological and surgical characteristics at RARP over time (2004-2010, 2011-2012 and 2013) were assessed. RESULTS: Overall, 1783 RARP patients were identified. Of those, 407 (22.8%), 764 (42.8%) and 612 (34.3%) were treated between 2004 and 2010, in 2011-2012 and in 2013, respectively. Unfavorable characteristics rate, such as biopsy Gleason Score ≥4+4 (8 vs. 9 vs. 15%, P<0.001), D'Amico high-risk (12 vs. 14 vs. 19%, P=0.001) and pathological Gleason score ≥4+4 (3 vs. 4 vs. 6%, P<0.001) increased over time. Pelvic lymph node dissection (PLND) was more frequently performed over time (62 vs. 83 vs. 84%, P<0.001), especially in D'Amico intermediate or high-risk patients (82 vs. 94 vs. 96%, P<0.001). Lymph node yield increased over time in overall (7 vs. 9 vs. 13, P<0.001), D'Amico intermediate (6 vs. 9 vs. 12, P<0.001) and D'Amico high-risk patients (9 vs. 12 vs. 18, P<0.001). No differences in surgical margin (P=0.7) and nerve sparing rates (P=0.09) were found. CONCLUSIONS: A clear trend towards more unfavorable tumor characteristics over time was recorded. Additionally, the rates and extent of PLND increased with increasing experience. RAR P does not represent a barrier to PLND at our institution.
BACKGROUND:Patients treated with robot-assisted radical prostatectomy (RARP) are frequently selected according to more favorable characteristics. Such patient selection might decrease according to increasing experience. METHODS: We relied on the Martini Clinic Prostate Cancer Center database and focused on patients treated with RARP between 2004 and 2013. Differences in clinical, pathological and surgical characteristics at RARP over time (2004-2010, 2011-2012 and 2013) were assessed. RESULTS: Overall, 1783 RARP patients were identified. Of those, 407 (22.8%), 764 (42.8%) and 612 (34.3%) were treated between 2004 and 2010, in 2011-2012 and in 2013, respectively. Unfavorable characteristics rate, such as biopsy Gleason Score ≥4+4 (8 vs. 9 vs. 15%, P<0.001), D'Amico high-risk (12 vs. 14 vs. 19%, P=0.001) and pathological Gleason score ≥4+4 (3 vs. 4 vs. 6%, P<0.001) increased over time. Pelvic lymph node dissection (PLND) was more frequently performed over time (62 vs. 83 vs. 84%, P<0.001), especially in D'Amico intermediate or high-risk patients (82 vs. 94 vs. 96%, P<0.001). Lymph node yield increased over time in overall (7 vs. 9 vs. 13, P<0.001), D'Amico intermediate (6 vs. 9 vs. 12, P<0.001) and D'Amico high-risk patients (9 vs. 12 vs. 18, P<0.001). No differences in surgical margin (P=0.7) and nerve sparing rates (P=0.09) were found. CONCLUSIONS: A clear trend towards more unfavorable tumor characteristics over time was recorded. Additionally, the rates and extent of PLND increased with increasing experience. RAR P does not represent a barrier to PLND at our institution.
Authors: Sophie Knipper; Moritz Hagedorn; Maryam Sadat-Khonsari; Zhe Tian; Pierre I Karakiewicz; Derya Tilki; Hans Heinzer; Uwe Michl; Thomas Steuber; Franziska von Breunig; Christian Zöllner; Markus Graefen Journal: World J Urol Date: 2019-09-06 Impact factor: 4.226